Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation
Recruitment status was: Recruiting
The effect of haematopoietic growth factors on neutrophil recovery after allogeneic bone marrow transplantation is well recognized. Recent laboratory studies demonstrated that these cytokines may also modify T-cell and dendritic cell function, but whether the effect is strong enough to alter the risk of graft-versus-host disease (GvHD) is unclear.
The aim of this randomised study is to determine the effect of granulocyte colony-stimulating factor [G-CSF] (Neupogen; filgrastim) on the risk of acute GvHD after allogeneic bone marrow transplantation.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Randomized Trial of Filgrastim Versus Placebo Following Allogeneic Bone Marrow Transplantation|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00207792
|Centre National de Greffe de Moelle Osseuse|
|Principal Investigator:||Tarek Ben Othman, MD||Centre National de Greffe de Moelle Osseuse|